CTXR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Citius Pharmaceuticals Inc (CTXR) is not a strong buy for a beginner, long-term investor at this moment. While the company has positive developments in its oncology product LYMPHIR and strong market acceptance, its financial performance is weak, with declining net income and EPS. Technical indicators are mixed, and there are no strong trading signals or significant upward momentum to justify immediate entry.
The MACD is positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 60.377, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key resistance levels, with a pivot at 0.791 and resistance at 0.893. Overall, the technical outlook is mixed, with no clear upward trend.
LYMPHIR has gained strong market acceptance, with 83% of target institutions including it in their formularies and 135 health plans providing coverage.
The company is expanding its international presence through distribution agreements in Europe and the Middle East.
Collaboration with academic institutions for clinical studies shows potential for further product development.
Financial performance is weak, with a 15.84% YoY drop in net income and a 70.77% YoY decline in EPS for Q1
No significant hedge fund or insider trading activity indicates a lack of strong institutional confidence.
The stock has a 70% chance of a slight decline (-2.45%) over the next month based on candlestick pattern analysis.
In Q1 2026, revenue remained flat YoY at $3,944,111, but net income dropped to -$8,220,785 (-15.84% YoY), and EPS fell to -0.38 (-70.77% YoY). Gross margin improved slightly to 79.99%. Overall, the financials show weak profitability and declining earnings.
No recent analyst ratings or price target changes are available for CTXR.
